Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;176(1):27-36.
doi: 10.1007/s10549-019-05233-9. Epub 2019 Apr 17.

Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer

I Noordhoek  1   2 , A F de Groot  3 , D Cohen  4 , G J Liefers  5 , J E A Portielje  3 , J R Kroep  3
Affiliations
Review

Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer

I Noordhoek et al. Breast Cancer Res Treat. 2019 Jul.

Abstract

Purpose: In breast cancer, hormone receptor (HR) status is generally a qualitative measure; positive or negative. Quantitatively measured oestrogen and progesterone receptors (ER and PR) are frequently proposed prognostic and predictive markers, some guidelines even provide different treatment options for patients with strong versus weak expression.

Aim: To evaluate quantitative HR load assessed by immunohistochemistry as a prognostic and predictive measure in stage 1-3 breast cancer.

Methods: We reviewed all the available literature on quantitatively measured HRs using immunohistochemistry.

Results: All included studies (n = 19) comprised a cohort of 30,754 patients. Only 2 out of 17 studies found a clear correlation between higher quantitative ER and better disease outcome. Only one trial examined quantitative ER both as prognostic and predictive marker and found no association between ER% and survival. Ten studies examined quantitative PR load, only two of those found a significant correlation between higher PR load and better disease outcome. Two trials examined quantitative PR both as prognostic and predictive marker, neither found any association between PR% and disease outcome.

Conclusions: There is no clear evidence for using quantitatively assessed ER and PR as prognostic nor predictive marker in patients with stage 1-3 breast cancer. We recommend only using a qualitative HR status in future guidelines and treatment considerations.

Keywords: Endocrine therapy; Estrogen receptor; Hormone receptor; Immunohistochemistry; Progesterone receptor; Quantitative assessment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
CONSORT diagram to account for excluded studies. ER Oestrogen receptor, PR Progesterone receptor, IHC Immunohistochemistry
Fig. 2
Fig. 2
Distribution of types of endocrine therapy over patients. TAM Tamoxifen, AI Aromatase inhibitor, ET Endocrine therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. - PMC - PubMed
    1. Dekker TJ, Smit VT, Hooijer GK, Van de Vijver MJ, Mesker WE, Tollenaar RA, Nortier JW, Kroep JR. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol. 2013;24(4):931–937. - PubMed
    1. Dekker TJA, ter Borg S, Hooijer GKJ, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CHM, Sleddens HFBM, Mesker WE, Kroep JR, Smit VTHBM, van de Vijver MJ. Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. Breast Cancer Res Treat. 2015;152(2):247–252. - PMC - PubMed
    1. Heuson JC, Longeval E, Mattheiem WH, Deboel MC, Sylvester RJ, Leclercq G. Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer. 1977;39(5):1971–1977. - PubMed
    1. McGuire WL. Steroid hormone receptors in breast cancer treatment strategy. Recent Prog Horm Res. 1980;36:135–156. - PubMed